In previous study, we confirmed in TCGA-AML cohort that high DC-STAMP expression was significantly associated with shortened overall survival across all AML genetic subtypes, including patients classified as ELN2022 low-risk. The gene discussed is DCSTAMP; the disease is acute myeloid leukemia.